Long QT syndrome 5

Common Name(s)

Long QT syndrome 5

Congenital long QT syndrome is electrocardiographically characterized by a prolonged QT interval and polymorphic ventricular arrhythmias (torsade de pointes). These cardiac arrhythmias may result in recurrent syncopes, seizure, or sudden death ({1:Jongbloed et al., 1999}).
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Long QT syndrome 5" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Long QT syndrome 5" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Long QT syndrome 5" returned 4 free, full-text research articles on human participants. First 3 results:

The human Nav1.5 F1486 deletion associated with long QT syndrome leads to impaired sodium channel inactivation and reduced lidocaine sensitivity.
 

Author(s): Weihua Song, Yucheng Xiao, Hanying Chen, Nicole M Ashpole, Andrew D Piekarz, Peilin Ma, Andy Hudmon, Theodore R Cummins, Weinian Shou

Journal: J. Physiol. (Lond.). 2012 Oct;590(Pt 20):5123-39.

 

The deletion of phenylalanine 1486 (F1486del) in the human cardiac voltage-gated sodium channel (hNav1.5) is associated with fatal long QT (LQT) syndrome. In this study we determined how F1486del impairs the functional properties of hNav1.5 and alters action potential firing in heterologous ...

Last Updated: 19 Oct 2012

Go To URL
Nadolol block of Nav1.5 does not explain its efficacy in the long QT syndrome.
 

Author(s): Alessandra Besana, Dao W Wang, Alfred L George, Peter J Schwartz

Journal: J. Cardiovasc. Pharmacol.. 2012 Mar;59(3):249-53.

 

Beta-adrenergic receptor antagonists (β-blockers) are the therapy of choice for the long QT syndrome but their efficacy is not homogeneous: propranolol and nadolol are the most effective, whereas metoprolol is associated with more treatment failures. Propranolol has a blocking effect ...

Last Updated: 7 Mar 2012

Go To URL
Mechanisms of disease pathogenesis in long QT syndrome type 5.
 

Author(s): Stephen C Harmer, Andrew J Wilson, Robert Aldridge, Andrew Tinker

Journal: Am. J. Physiol., Cell Physiol.. 2010 Feb;298(2):C263-73.

 

KCNE1 associates with the pore-forming alpha-subunit KCNQ1 to generate the slow (I(Ks)) current in cardiac myocytes. Mutations in either KCNQ1 or KCNE1 can alter the biophysical properties of I(Ks) and mutations in KCNE1 underlie cases of long QT syndrome type 5 (LQT5). We previously ...

Last Updated: 25 Jan 2010

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Long QT syndrome 5" returned 0 free, full-text review articles on human participants.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

There are currently no open clinical trials for this condition.